Vivos Therapeutics, Inc. (VVOS)

NASDAQ: VVOS · IEX Real-Time Price · USD

2.720

+0.060 (2.26%)

At close: Apr 19, 2024, 4:00 PM

2.650

-0.070 (-2.57%)

After-hours: Apr 19, 2024, 6:58 PM EDT

Vivos Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Revenue	13.8	16.02	16.89	13.07	11.39	3.79
Revenue Growth (YoY)	-13.87%	-5.10%	29.23%	14.68%	200.43%	-
Cost of Revenue	5.53	6.01	4.28	2.65	2.74	1.08
Gross Profit	8.27	10.02	12.6	10.41	8.66	2.71
Selling, General & Admin	24.95	34.38	31.34	18.4	18.48	10.44
Other Operating Expenses	0.62	0.67	1.64	4.05	0.75	0.61
Operating Expenses	25.57	35.05	32.99	22.45	19.23	11.05
Operating Income	-17.3	-25.03	-20.38	-12.04	-10.58	-8.34
Interest Expense / Income	0	0	0.01	0.1	0.14	0.1
Other Expense / Income	-3.71	-1.19	-0.11	-0.08	0.04	-
Pretax Income	-13.58	-23.85	-20.29	-12.06	-10.75	-8.44
Net Income	-13.58	-23.85	-20.29	-12.06	-10.75	-8.44
Preferred Dividends	0	0	0	5.93	1	1
Net Income Common	-13.58	-23.85	-20.29	-17.99	-11.75	-9.44
Shares Outstanding (Basic)	1	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	1	0	0
Shares Change	32.46%	8.39%	65.00%	4.36%	6.78%	-
EPS (Basic)	-11.14	-25.90	-24.00	-35.00	-23.75	-20.50
EPS (Diluted)	-11.14	-25.90	-24.00	-35.00	-23.75	-20.50
Free Cash Flow	-12.8	-20.51	-18.13	-5.8	-5.52	-6.56
Free Cash Flow Per Share	-10.50	-22.28	-21.35	-11.27	-11.18	-14.21
Gross Margin	59.93%	62.52%	74.65%	79.70%	75.99%	71.48%
Operating Margin	-125.32%	-156.21%	-120.71%	-92.15%	-92.84%	-219.82%
Profit Margin	-98.42%	-148.81%	-120.15%	-137.67%	-103.17%	-248.91%
Free Cash Flow Margin	-92.74%	-128.00%	-107.38%	-44.39%	-48.42%	-173.10%
EBITDA	-12.96	-23.18	-19.54	-11.24	-9.87	-7.73
EBITDA Margin	-93.92%	-144.63%	-115.73%	-86.05%	-86.59%	-203.72%
Depreciation & Amortization	0.62	0.67	0.73	0.72	0.75	0.61
EBIT	-13.58	-23.85	-20.27	-11.96	-10.62	-8.34
EBIT Margin	-98.42%	-148.81%	-120.07%	-91.54%	-93.18%	-219.82%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).